Free shipping on all orders over $ 500

MK-3697

Cat. No. M3710
MK-3697 Structure
Size Price Availability Quantity
5mg USD 160 In stock
10mg USD 270 In stock
50mg USD 820 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

MK3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. MK-3697 is also the third insomnia product, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 447.51
Formula C23H21N5O3S
CAS Number 1224846-01-8
Purity >99%
Solubility DMSO 22 mg/mL
Storage at -20°C
References

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ, et al. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90. PMID: 25248679.

Related OX Receptor Products
SB-334867

SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.

TCS-1102

TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).

SB408124

SB408124 (Tocris-1963) is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.

Suvorexant

Suvorexant (MK-4305) is a potent, selective and orally bioavailable antagonist of OX(1)R and OX(2)R for the treatment of insomnia.

MK-6096

MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: MK-3697 supplier, OX Receptor, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.